Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Flu Vaccine Deal with BIKEN Hoped to Yield Synergies in Elderly Products: MSD Pres. Alvarez
September 5, 2012
- Anticancer Agent Enzalutamide Approved in the US: Astellas
September 5, 2012
- Halaven Approved in South Korea, To Be Launched in Jan. 2013: Eisai
September 5, 2012
- RaQualia to Focus on Fields Where It Can Exhibit Uniqueness, Compile Biz Strategy in November
September 4, 2012
- “Advancements in Domestic Business is Growth Driver” for Achieving Midterm Business Plan : MTPC President Tsuchiya
September 4, 2012
- Ono Ties Up with BioFocus of the UK for Drug Discovery for CNS Disorders
September 4, 2012
- Meiji Seika Pharma Launches COPD Treatment Oxis, Detailed by More Than 600 MRs
September 4, 2012
- Otsuka Applies for Abilify as Adjunctive Therapy for Depression; First Indication for Antipsychotic Drug in Japan
September 4, 2012
- MTPC to Double Number of Vaccine-Specialized MRs to 50, Eyeing TETRABIK Launch
September 3, 2012
- DSP’s US Subsidiary Sunovion to Acquire Elevation Pharmaceuticals of the US
September 3, 2012
- Shionogi to Embark on Collaborative R&D with 5 Danish Universities
September 3, 2012
- MTPC and Nipro Agree on Dissolution of Joint Venture Bipha
September 3, 2012
- 9 Companies Jointly Apply for Combination Use of 3 Agents for H. Pylori Eradication
September 3, 2012
- Wholesalers and Pharmacies See Contrasting Results in 1st Quarter – Which Side Will Come Out the Winner from Non-yieldable Price Bargaining?
September 3, 2012
- Sosei Committed to Becoming a Japan-Based Global Biopharma: Vice President Akihiro Matsuura
September 3, 2012
- Pfizer Japan Launches RCC Treatment Inlyta
August 31, 2012
- Takeda to Conduct Joint Research with Canadian Institute at Shonan Research Center
August 31, 2012
- Eisai Files NDA for Rufinamide for LGS
August 31, 2012
- Novartis to File for COPD Treatment QVA149 in Japan, EU by End of 2012
August 31, 2012
- Kyowa Kirin Temporarily Suspends Patient Enrollment for PIII Study of Its Anticancer Agent ARQ197 Due to ADR
August 31, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…